Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...

Weight-loss drugs such as Ozempic and Zepbound cost $900 to $1,500 for a month's supply.They cost so much partly because of ...

Eli Lilly kicks off 2025 with key licensing deals and M&A, boosting its position across therapeutic areas amid rising drug ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn ...

Congressional lawmakers were told earlier this month about the staggering price tag in taxpayer money used to conduct studies ...

Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by ...

The Braves would love to get Anderson back to top form, as the right-hander is 4-0 with a 1.25 ERA in the postseason.

Eli Lilly's stock offers high growth potential, driven by GLP-1 therapies and strong R&D efforts. Read why LLY stock is ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Star point guard commit, Eli Ellis, has earned back-to-back MVP honors in the prestigious Overtime Elite (OTE) league, widely ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen ...